Biomarkers of Cellular Senescence and Skin Aging.

Wang AS, Dreesen O. · 2018

Read Biomarkers of Cellular Senescence and Skin Aging. by Wang AS, Dreesen O. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6115505.txt.

Introduction

Wang and Dreesen wrote a review in Frontiers in Genetics on markers of cell aging, with a focus on skin. Cells that stop dividing for good are called senescent. They build up in aged skin and may drive many age-linked skin changes. Finding them in tissue has been hard, since no single marker fits all cells.

The review checks the markers now in use. It asks how well each one spots aged cells in each skin layer and cell type. Clearing such cells can delay tissue decline in lab work. The authors weigh what each marker can and cannot prove. Readers get a guide to a key tool problem in aging research.

Catalog record

CREATORWang AS, Dreesen O.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE84 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6115505

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Biomarkers of Cellular Senescence and Skin Aging By Audrey S Wang, Oliver Dreesen Published in: Frontiers in Genetics DOI: 10.3389/fgene.2018.00247 ABSTRACT Abstract Cellular senescence is an irreversible growth arrest that occurs as a result of different damaging stimuli, including DNA damage, telomere shortening and dysfunction or oncogenic stress. Senescent cells exert a pleotropic effect on development, tissue aging and regeneration, inflammation, wound healing and tumor suppression. Strategies to remove senescent cells from aging tissues or preneoplastic lesions can delay tissue dysfunction and lead to increased healthspan. However, a significant hurdle in the aging field has been the identification of a universal biomarker that facilitates the unequivocal detection and quantification of senescent cell types in vitro and in vivo. Mammalian skin is the largest organ of the human body and consists of different cell types and compartments. Skin provides a physical barrier against harmful microbes, toxins, and protects us from ultraviolet radiation. Increasing evidence suggests that senescent cells accumulate in chronologically aged and photoaged skin; and may contribute to age-related skin changes and pathologies. Here, we highlight current biomarkers to detect senescent cells and review their utility in the context of skin aging. In particular, we discuss the efficacy of biomarkers to detect senescence within different skin compartments and cell types, and how they may contribute to myriad manifestations of skin aging and age-related skin pathologies. Keywords: senescence, skin, aging, biomarkers, photoaging, cancer CELLULAR SENESCENCE AND ORGANISMAL AGING Aging is the result of a gradual functional decline at the cellular, and ultimately, organismal level, resulting in the development of myriad chronic illnesses including heart disease, stroke and diabetes. On a cellular level, aging was first described by Hayflick and Moorhead (1961), who demonstrated that somatic mammalian cells have a finite propensity for cell division, after which they enter an irreversible growth arrest termed cellular senescence. Senescent cells are characterized by their inability to proliferate, resistance to apoptosis, and secretion of factors that promote inflammation and tissue deterioration (Campisi and d’Adda di Fagagna, 2007; Kuilman et al., 2010; He and Sharpless, 2017). The molecular basis underlying Hayflick’s observations came to light only decades later. In the early 1970s, Watson and Olovnikov proposed that during semi-conservative DNA replication of linear chromosomes, the removal of the terminal RNA primer, required to initiate lagging strand synthesis, would result in a gap that can no longer be filled by conventional DNA polymerases. As a result of this “end replication problem", chromosome terminal sequences, termed telomeres (Blackburn and Challoner, 1984) shorten during each replication cycle (Hayflick and Moorhead, 1961; Watson, 1972; Olovnikov, 1973; Allsopp et al., 1992). Critically shortened telomeres trigger a persistent activation of DNA damage response (DDR) pathways, thereby resulting in cellular senescence (D’Adda Di Fagagna et al., 2003). It is now clear that several types of cellular stressors can trigger senescence. These include telomere shortening and dysfunction (D’Adda Di Fagagna et al., 2003; Takai et al., 2003), inadvertent activation of oncogenes, termed oncogene-induced senescence (OIS) (Serrano et al., 1997; Michaloglou et al., 2005; Suram et al., 2012), changes in chromatin structure and epigenetic stress (Bakkenist and Kastan, 2003; Munro et al., 2004), oxidative stress, mitochondrial dysfunction (Wiley et al., 2016), or persistent activation of DNA damage checkpoints (D’Adda Di Fagagna et al., 2003; Rodier et al., 2009). There is increasing evidence suggesting that senescent cells accumulate in aging tissues and organs, thereby impairing physiological processes, including regeneration, and contributing to organismal aging (Dimri et al., 1995; Krishnamurthy et al., 2004; Jeyapalan et al., 2007). SENESCENCE BIOMARKERS The identification of unique markers that unequivocally detect and quantify senescent cells, particularly in vivo, remains challenging (Sharpless and Sherr, 2015). Senescent cells display an enlarged and flattened cell shape (Hayflick, 1965; Chen et al., 2000, 2008), and elevated senescence-associated β-galactosidase (SA-β-gal) activity, which remains the gold standard to identify senescent cells in culture and tissue samples (Dimri et al., 1995; Debacq-Chainiaux et al., 2009). However, this assay requires active enzymatic SA-β-gal activity, which is retained in fresh tissue samples but often lost in fixed or cryopreserved tissues (Severino et al., 2000; Lee et al., 2006). In addition, non-specific SA-β-gal activity can be detected in early passage adult melanocytes proliferating in culture, in hair follicles, sebaceous glands, and eccrine glands and ducts in both young and old human skin (Dimri et al., 1995), as well as in proliferating surface luminal cells of the duodenum (Going et al., 2002). Importantly, it remains difficult to multiplex the conventional detection method for SA-β-gal with other senescence-associated or cell-type specific markers, hence limiting the ability to identify senescent cell types or populations within a complex tissue or organ. Toward this goal, a modified flow cytometry-based method of multiplexing SA-β-gal with other senescence markers has been reported (Biran et al., 2017). However, such multiplexing strategies involving SA-β-gal in tissue biopsies in situ remains laborious. Despite being a hallmark of senescent cells, SA-β-gal activity does not play a mechanistic role in triggering senescence: cells from patients with autosomal recessive G(M1)-gangliosidosis lack lysosomal β-gal activity, but retain their ability to senesce (Lee et al., 2006). As senescent cells are terminally growth arrested, cell cycle regulators such as p16INK4a, p21CIP1 and p53 (Collado and Serrano, 2010) are commonly employed to detect senescent cells. p16INK4a, p21CIP1 and p53 were simultaneously upregulated in human skin fibroblasts post-ultraviolet (UV) radiation (Chen et al., 2008). p16INK4a plays a key role in cell cycle control upstream of the retinoblastoma tumor suppressor protein, and p16INK4a-positive senescent cells accumulate in an age-dependent manner in multiple tissues including the skin (Zindy et al., 1997; Krishnamurthy et al., 2004; Michaloglou et al., 2005; Herbig et al., 2006; Ressler et al., 2006; Coppé et al., 2011; Waaijer et al., 2012). p16INK4a-positive cells accumulate in preneoplastic lesions, including melanocyte-rich benign human nevi, caused by activating mutations in N-RAS or its downstream target BRAF (Michaloglou et al., 2005; Ivanov et al., 2013). Considering the role of p16INK4a in mediating senescence, it is not surprising that this locus is frequently mutated in a variety of human cancers, including skin epithelial tumors (Soufir et al., 1999; De Snoo et al., 2008). Although less well understood, senescence is also characterized by widespread chromatin remodeling. Normal cellular aging is associated with global heterochromatin loss, characterized by markers H3K9me3 and H3K27me3 (Tsurumi and Li, 2012). In agreement with these findings, cells from patients with the accelerated aging syndrome Hutchinson–Gilford progeria syndrome (HGPS) exhibit a profound loss of heterochromatin (Misteli and Scaffidi, 2005; Shumaker et al., 2006; Chojnowski et al., 2015). Predominantly during OIS in vitro, heterochromatin is redistributed into 30–50 punctate DNA-dense senescence-associated heterochromatin foci (SAHF). SAHF are silent domains that co-localize with H3K9me3 and heterochromatin protein 1 (HP1) and may lock cells in a senescent state by transcriptionally repressing genes involved in cell proliferation (Narita et al., 2003; Sadaie et al., 2013; Shah et al., 2013). In contrast, SAHF formation was not observed in HGPS patient cells or preneoplastic lesions that express other senescence markers (Scaffidi and Misteli, 2006; Shumaker et al., 2006; Kosar et al., 2011; Ivanov et al., 2013). Long-term monitoring of senescent cells in vitro revealed progressive proteolysis of Histones 3 and 4 without DNA loss. Reduced histone content was also observed in nevus melanocytes, as compared to neighboring

Read the complete text